Study of a new medicine for hard-to-treat aplastic anemia
Part of Blood & lymphatic clinical trials.
This study tests a new medicine called CM313 for people with aplastic anemia that has not responded to standard treatments or has come back. The medicine is given as an injection under the skin and may help your bone marrow make more blood cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You need a clear diagnosis of aplastic anemia that has either returned or hasn't improved after treatment.
- You must be generally active and able to care for yourself (ECOG score 2 or lower).
- You cannot have certain inherited bone marrow failure conditions.
- You must not be pregnant or breastfeeding, and must agree to use birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new antibody drug (anti-CD38) for people with severe aplastic anemia that has not responded to or has come back after standard treatments. The goal is to see if this drug can help improve blood counts when other options have failed.
This trial tests a drug called daratumumab for people with aplastic anemia that hasn't improved with standard treatments. The goal is to see if it can help your bone marrow make more blood cells and improve your blood counts.
This study tests an experimental treatment made from special immune cells designed to help your body fight aplastic anemia. It may be an option if you still need blood transfusions despite standard treatments.
This study is testing whether a stem cell transplant (from a matched relative, unrelated donor, or half-matched donor) can help adults aged 40–60 with severe aplastic anemia that didn't get better or came back after standard treatments.
This trial tests a drug called romiplostim for people with aplastic anemia that did not get better with standard treatments. It aims to boost blood cell counts and may help reduce the need for transfusions.
This trial tests a new drug called CM313 to see if it can help people whose platelet transfusions stop working. It is for adults who need platelet transfusions and have developed antibodies against them.
Hear when a new Aplastic Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.